TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Life Sciences

    BiotechTV – News

    This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

    Advertise

    Copyright: © BiotechTV

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    From Oxford: Carlo Rinaldi's team has received two grants from Oxford-Harrington Rare Disease Centre to develop treatments for Spinal-bulbar muscular atrophy (SBMA) and Friedreich's ataxia Feb 17, 2026
    Show notes

    He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.

    From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases Feb 17, 2026
    Show notes

    He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.

    Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more Feb 13, 2026
    Show notes

    MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Aurora Therapeutics CEO Ed Kaye and DaCapo Brainscience CEO Leslie Williams about being biotech leaders during this volatile time for the industry. They stress that a key to success is that everyone in the industry work together towards shared goals.

    Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened Feb 12, 2026
    Show notes

    He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take on the recent Corvus atopic dermatitis data.

    Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist Feb 11, 2026
    Show notes

    He describes top-line data the company saw across three different doses, next steps, and also shares an update on additional indications of chronic rhinosinusitis with nasal polyps and COPD it is being developed for.

    Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib Jan 28, 2026
    Show notes

    He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.

    Analysts Thursdays: Clear Street Senior Biotech Analyst Kaveri Pohlman shares her take on biotech for 2026 and discusses her top picks Jan 22, 2026
    Show notes

    She discusses Arrivent Biopharma, Oruka Therapeutics, Jade Biosciences, Zura Bio, and Pavella Therapeutics.

    SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026 Jan 17, 2026
    Show notes

    He talks about Perceptive's investment philosophy, his take on the year ahead, areas he thinks are over and under hyped, and thoughts on China. Plus, the rationale for a few of his top holdings.

    SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO Jan 16, 2026
    Show notes

    He discussed the REMS, launch plans, market opportunity, payors, and the metrics that the company will offer publicly over time. Plus, previewing a key new data readout that will be coming in the second quarter of this year.

    SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes Jan 16, 2026
    Show notes

    He describes one patient data from an investigator led study in Europe, and explains how Sana's program is slighly different. The company aims to file an IND this year. Plus, discussing the company's unique delivery mechanism for in vivo CAR-T.

    Previous 1 11 12 13 14 15 49 Next

    Related Podcasts

    Science Friday

    1

    Science Friday Astronomy
    The Naked Scientists Podcast

    2

    The Naked Scientists Podcast Life Sciences
    Stuff To Blow Your Mind

    3

    Stuff To Blow Your Mind Life Sciences
    Stuff To Blow Your Mind

    4

    Stuff To Blow Your Mind Life Sciences
    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone

    5

    Brain Science with Ginger Campbell, MD: Neuroscience for Everyone Health & Fitness
    All In The Mind

    6

    All In The Mind Government & Organizations
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights